Grifols, S.A(NASDAQ:GRFS) 
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment...
Website: http://www.grifols.com
Founded: 1940
Full Time Employees: 24,000
Sector: Healthcare
Industry: Drug Manufacturers-General
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2025-07-30 | 2024-07-30 | 2024-02-29 | 2022-07-28 | 2021-07-29 | 2018-12-31 | 2014-12-31 | 2014-02-26 | 2013-12-31 | 2013-02-28 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
cost of sales | -7,957,000 | 210,817,000 | |||||||||
research and development | 181,000 | 54,673,000 | |||||||||
selling, general & administrative expenses | 35,477,000 | 308,738,000 | |||||||||
change in trade provisions | 2,283,750 | 9,135,000 | |||||||||
professional services | 21,826,000 | 99,641,000 | |||||||||
commission | 4,945,000 | 19,780,000 | |||||||||
supplies and auxiliary materials | -1,468,000 | 80,461,000 | |||||||||
operating leases | 1,531,000 | 67,991,000 | |||||||||
freight | 1,897,000 | 52,280,000 | |||||||||
repair and maintenance expenses | 4,986,000 | 50,256,000 | |||||||||
advertising | 4,686,000 | 43,429,000 | |||||||||
insurance | -567,000 | 16,745,000 | |||||||||
royalties | -1,993,000 | 5,824,000 | |||||||||
travel expenses | 5,905,000 | 27,353,000 | |||||||||
external services | -5,541,000 | 49,222,000 | |||||||||
other | 1,859,000 | 52,111,000 | |||||||||
other operating expenses | 27,701,000 | 574,228,000 |
Balance Sheets:
Cashflow Statements:
Quarterly
Annual
| Unit: USD |
|---|